Cargando…
Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells
Gene therapy holds great promise for treating prostate cancer unresponsive to conventional therapies. However, the lack of delivery systems that can transport therapeutic DNA and drugs while targeting tumors without harming healthy tissues presents a significant challenge. This study aimed to explor...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675605/ https://www.ncbi.nlm.nih.gov/pubmed/38004621 http://dx.doi.org/10.3390/pharmaceutics15112643 |
_version_ | 1785149834867507200 |
---|---|
author | Maeyouf, Khadeejah Sakpakdeejaroen, Intouch Somani, Sukrut Meewan, Jitkasem Ali-Jerman, Hawraa Laskar, Partha Mullin, Margaret MacKenzie, Graeme Tate, Rothwelle J. Dufès, Christine |
author_facet | Maeyouf, Khadeejah Sakpakdeejaroen, Intouch Somani, Sukrut Meewan, Jitkasem Ali-Jerman, Hawraa Laskar, Partha Mullin, Margaret MacKenzie, Graeme Tate, Rothwelle J. Dufès, Christine |
author_sort | Maeyouf, Khadeejah |
collection | PubMed |
description | Gene therapy holds great promise for treating prostate cancer unresponsive to conventional therapies. However, the lack of delivery systems that can transport therapeutic DNA and drugs while targeting tumors without harming healthy tissues presents a significant challenge. This study aimed to explore the potential of novel hybrid lipid nanoparticles, composed of biocompatible zein and conjugated to the cancer-targeting ligand transferrin. These nanoparticles were designed to entrap the anti-cancer drug docetaxel and carry plasmid DNA, with the objective of improving the delivery of therapeutic payloads to prostate cancer cells, thereby enhancing their anti-proliferative efficacy and gene expression levels. These transferrin-bearing, zein-based hybrid lipid nanoparticles efficiently entrapped docetaxel, leading to increased uptake by PC-3 and LNCaP cancer cells and significantly enhancing anti-proliferative efficacy at docetaxel concentrations exceeding 1 µg/mL. Furthermore, they demonstrated proficient DNA condensation, exceeding 80% at polymer–DNA weight ratios of 1500:1 and 2000:1. This resulted in increased gene expression across all tested cell lines, with the highest transfection levels up to 11-fold higher than those observed with controls, in LNCaP cells. These novel transferrin-bearing, zein-based hybrid lipid nanoparticles therefore exhibit promising potential as drug and gene delivery systems for prostate cancer therapy. |
format | Online Article Text |
id | pubmed-10675605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106756052023-11-20 Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells Maeyouf, Khadeejah Sakpakdeejaroen, Intouch Somani, Sukrut Meewan, Jitkasem Ali-Jerman, Hawraa Laskar, Partha Mullin, Margaret MacKenzie, Graeme Tate, Rothwelle J. Dufès, Christine Pharmaceutics Article Gene therapy holds great promise for treating prostate cancer unresponsive to conventional therapies. However, the lack of delivery systems that can transport therapeutic DNA and drugs while targeting tumors without harming healthy tissues presents a significant challenge. This study aimed to explore the potential of novel hybrid lipid nanoparticles, composed of biocompatible zein and conjugated to the cancer-targeting ligand transferrin. These nanoparticles were designed to entrap the anti-cancer drug docetaxel and carry plasmid DNA, with the objective of improving the delivery of therapeutic payloads to prostate cancer cells, thereby enhancing their anti-proliferative efficacy and gene expression levels. These transferrin-bearing, zein-based hybrid lipid nanoparticles efficiently entrapped docetaxel, leading to increased uptake by PC-3 and LNCaP cancer cells and significantly enhancing anti-proliferative efficacy at docetaxel concentrations exceeding 1 µg/mL. Furthermore, they demonstrated proficient DNA condensation, exceeding 80% at polymer–DNA weight ratios of 1500:1 and 2000:1. This resulted in increased gene expression across all tested cell lines, with the highest transfection levels up to 11-fold higher than those observed with controls, in LNCaP cells. These novel transferrin-bearing, zein-based hybrid lipid nanoparticles therefore exhibit promising potential as drug and gene delivery systems for prostate cancer therapy. MDPI 2023-11-20 /pmc/articles/PMC10675605/ /pubmed/38004621 http://dx.doi.org/10.3390/pharmaceutics15112643 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maeyouf, Khadeejah Sakpakdeejaroen, Intouch Somani, Sukrut Meewan, Jitkasem Ali-Jerman, Hawraa Laskar, Partha Mullin, Margaret MacKenzie, Graeme Tate, Rothwelle J. Dufès, Christine Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title | Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title_full | Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title_fullStr | Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title_full_unstemmed | Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title_short | Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells |
title_sort | transferrin-bearing, zein-based hybrid lipid nanoparticles for drug and gene delivery to prostate cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675605/ https://www.ncbi.nlm.nih.gov/pubmed/38004621 http://dx.doi.org/10.3390/pharmaceutics15112643 |
work_keys_str_mv | AT maeyoufkhadeejah transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT sakpakdeejaroenintouch transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT somanisukrut transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT meewanjitkasem transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT alijermanhawraa transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT laskarpartha transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT mullinmargaret transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT mackenziegraeme transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT taterothwellej transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells AT dufeschristine transferrinbearingzeinbasedhybridlipidnanoparticlesfordrugandgenedeliverytoprostatecancercells |